This analysis of claims data from a large managed care database demonstrated that significant variability exists in the frequency of dosing of ARB products. Because this therapeutic class contains many higher-cost antihypertensive agents, observed differences in DACON scores may have significant economic and design implications for health plans and managed care formularies. Variable ARB dosing potentially could also affect quality of care, in addition to overall costs.
However, these conclusions are limited by lack of clinical information. Further real-world evaluations of ARBs are warranted to address the impact of variations in utilization on clinical effectiveness.
© 2005 Cliggott Publishing, Division of CMP Healthcare Media
Cite this: A Retrospective Database Analysis of Prescribing Patterns for Specific Angiotensin Receptor Blockers - Medscape - Jan 01, 2005.